JP2017514875A - 失禁および他の括約筋不全障害を処置する方法 - Google Patents

失禁および他の括約筋不全障害を処置する方法 Download PDF

Info

Publication number
JP2017514875A
JP2017514875A JP2016566943A JP2016566943A JP2017514875A JP 2017514875 A JP2017514875 A JP 2017514875A JP 2016566943 A JP2016566943 A JP 2016566943A JP 2016566943 A JP2016566943 A JP 2016566943A JP 2017514875 A JP2017514875 A JP 2017514875A
Authority
JP
Japan
Prior art keywords
sphincter
sdf
disorder
incontinence
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514875A5 (cg-RX-API-DMAC7.html
Inventor
ウィリアムズ，ジェイムズ・ケイ
Original Assignee
ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ filed Critical ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ
Publication of JP2017514875A publication Critical patent/JP2017514875A/ja
Publication of JP2017514875A5 publication Critical patent/JP2017514875A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016566943A 2014-05-08 2015-04-30 失禁および他の括約筋不全障害を処置する方法 Pending JP2017514875A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990190P 2014-05-08 2014-05-08
US61/990,190 2014-05-08
PCT/US2015/028490 WO2015171417A1 (en) 2014-05-08 2015-04-30 Methods of treating incontinence and other sphincter deficiency disorders

Publications (2)

Publication Number Publication Date
JP2017514875A true JP2017514875A (ja) 2017-06-08
JP2017514875A5 JP2017514875A5 (cg-RX-API-DMAC7.html) 2018-06-14

Family

ID=54392862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566943A Pending JP2017514875A (ja) 2014-05-08 2015-04-30 失禁および他の括約筋不全障害を処置する方法

Country Status (6)

Country Link
US (2) US10420818B2 (cg-RX-API-DMAC7.html)
EP (1) EP3139945B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017514875A (cg-RX-API-DMAC7.html)
AU (1) AU2015256383B2 (cg-RX-API-DMAC7.html)
CA (1) CA2946761C (cg-RX-API-DMAC7.html)
WO (1) WO2015171417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3139945B1 (en) 2014-05-08 2025-08-27 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
CA3055761A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
US11654181B2 (en) 2017-08-11 2023-05-23 Wake Forest University Health Sciences Use of CXCL12 for therapy after prostate surgery
CN114159471A (zh) * 2020-09-11 2022-03-11 永立荣生医股份有限公司 包括羊水干细胞球的医药组合物及其治疗尿失禁的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6363624A (ja) * 1986-09-04 1988-03-22 Etsuko Kakizaki 徐放性注射剤
JP2009508650A (ja) * 2005-09-21 2009-03-05 ダスク テクノロジーズ， エルエルシー 臓器および組織機能のための方法および組成
US20100272679A1 (en) * 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US311219A (en) 1885-01-27 Mechanical toy
US5385561A (en) 1994-01-18 1995-01-31 Bard International, Inc. Apparatus and method for injecting a viscous material into the tissue of a patient
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
US5925629A (en) 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
EP1290033B1 (en) 2000-06-05 2012-10-31 The Trustees of Columbia University in the City of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
AU2002322493A1 (en) 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
AU2005287855B2 (en) * 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
US7939057B2 (en) 2006-01-25 2011-05-10 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US7598028B2 (en) 2006-11-28 2009-10-06 The Regents Of The University Of Michigan Compositions and methods for detecting and treating prostate disorders
BRPI0813352A2 (pt) * 2007-06-15 2014-12-30 Ethicon Inc Composições de fragmento de tecido para o tratamento de incontinência
JP5248519B2 (ja) * 2007-11-07 2013-07-31 小野薬品工業株式会社 Ｓｄｆ−１を含有してなる徐放性組成物
BRPI0917135A2 (pt) 2008-08-09 2015-11-10 Massachusetts Inst Technology dispositivo médico para extensão e retenção em uma vesícula seminal, duto ejaculatório, próstata ou vaso deferente de um paciente, uso de um elastômero reabsorvível, e, dispositivo de bomba osmótica.
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
US9308277B2 (en) * 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP3139945B1 (en) 2014-05-08 2025-08-27 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6363624A (ja) * 1986-09-04 1988-03-22 Etsuko Kakizaki 徐放性注射剤
JP2009508650A (ja) * 2005-09-21 2009-03-05 ダスク テクノロジーズ， エルエルシー 臓器および組織機能のための方法および組成
US20100272679A1 (en) * 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NEUROUROLOGY AND URODYNAMICS, vol. 32(6), JPN6019000712, 2013, ISSN: 0004292882 *
THE JOURNAL OF UROLOGY, vol. 179, JPN6019000713, January 2008 (2008-01-01), pages 226 - 231, ISSN: 0004292883 *
メルクマニュアル, vol. 第18版初版第3刷,日本語版, JPN6020022213, 25 April 2007 (2007-04-25), pages 2071 - 2081, ISSN: 0004292884 *

Also Published As

Publication number Publication date
AU2015256383B2 (en) 2020-05-21
WO2015171417A1 (en) 2015-11-12
NZ727292A (en) 2024-03-22
AU2015256383A1 (en) 2017-01-05
EP3139945B1 (en) 2025-08-27
CA2946761A1 (en) 2015-11-12
EP3139945A1 (en) 2017-03-15
US20190365860A1 (en) 2019-12-05
US11160848B2 (en) 2021-11-02
US20170106050A1 (en) 2017-04-20
US10420818B2 (en) 2019-09-24
EP3139945A4 (en) 2017-11-29
CA2946761C (en) 2023-08-22

Similar Documents

Publication Publication Date Title
JP7590724B2 (ja) 炎症性腸疾患の治療薬
US11160848B2 (en) Methods of treating gastrointestinal sphincter deficiency disorders
KR20160117519A (ko) 노화 세포를 사멸시키고 노화 관련 질환 및 장애를 치료하기 위한 방법 및 조성물
KR20160021084A (ko) 사람에서 고형 종양의 치료를 위한 씨. 노비
JP2025069172A (ja) 腎臓疾患の治療方法
Radtke et al. Palifermin (Kepivance™) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support
JP7390370B2 (ja) 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ
KR20210152531A (ko) 종양을 치료하는 방법
TWI828155B (zh) 吡咯并嘧啶類化合物的用途
AU2017342551A2 (en) Methods of treatment and pharmaceutical compositions using BCN057 or BCN512
JP7514563B2 (ja) オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物
Williams et al. Methods of treating incontinence and other sphincter deficiency disorders
US11654181B2 (en) Use of CXCL12 for therapy after prostate surgery
CN101406695A (zh) 促进脊髓损伤中轴突再生和行为功能恢复的药物组合物
US20250295812A1 (en) Treatment for osteoarthritis
CA2177570A1 (en) Method of treating intestinal disorders
ES2903411T3 (es) AMD3100 para el tratamiento y/o la prevención de caquexia, y composición farmacéutica del mismo
JP2024020797A (ja) 筋萎縮の治療剤
WO2020262527A1 (ja) 筋再生促進剤
Zhang et al. e0192 A metaanalysis of right ventricular septum pacing
EA044461B1 (ru) Способ лечения опухолей
Weishaupt Promoting Neuroplasticity To Repair The Injured Spinal Cord
Bekdash et al. IL-33 Induces Type-2-Cytokine Phenotype but Exacerbates Cardiac Remodeling Post-Myocardial Infarction with Eosinophil Recruitment, Worsened Systolic 2 Dysfunction, and Ventricular Wall Rupture 3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200423

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200424

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200626

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200630

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210105

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210402

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210521

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20210521

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20210521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211020

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211224

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220128

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220128